Many people may not want to divulge their bathroom dramas to a doctor, or anyone, or may think that heartburn is common and no big deal. Everyone gets a tummy ache now and again, but if you have diabetes, GI symptoms may indicate that something is chronically wrong. “If it bothers you, it’s worth getting checked out,” says Bragg. With a proper diagnosis, you and your health care provider can come up with a plan to make your whole body feel a whole lot better.
Medications used to treat diabetes do so by lowering blood sugar levels. There is broad consensus that when people with diabetes maintain tight glucose control (also called "tight glycemic control") -- keeping the glucose levels in their blood within normal ranges - that they experience fewer complications like kidney problems and eye problems. There is however debate as to whether this is cost effective for people later in life.
^ Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I (February 2010). "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials". Lancet. 375 (9716): 735–42. doi:10.1016/S0140-6736(09)61965-6. PMID 20167359.
Replacing humans with computers could make patients better control their sugar levels and suffer less complications in the long term. The French company Cellnovo has already shown that just a partially automated system, where blood sugar levels can be monitored wirelessly but patients still select insulin amounts, can reduce the chances of reaching life-threatening low sugar levels up to 39%. The company is now working towards developing a fully automated artificial pancreas in collaboration with Imperial College, the Diabeloop consortium and the Horizon2020 program.
Preventative soon drew enough attention that The New York Mirror devoted a whole column to it in the newspaper's March 6, 1824, edition. "The conversion of preventive into preventative is an error too common," wrote the anonymous scribe. "Some fall into it from ignorance, and others from inadvertence." The writer attributed its use to "a disposition in people to spell words with more letters than belong to them; or to insert a syllable or syllables, where addition, so far from being advisable or requisite, proves injurious." The column concluded with a call to action: "Let those, then, who from carelessness or any other cause, have been in the habit of using preventative, make it henceforth an invariable rule, whether in writing or in utterance, to prefer the proper and unexceptionable term preventive."
No matter the size of your organization—a WELCOA membership provides you with training and tools you need to change organizational culture, increase engagement, contain costs, and improve the lives of your employees. Ideal for workplace wellness and human resource professionals, benefits consultants and brokers—our solution encourages organizations to fuse knowledge and engage all team members to design your own highly personalized approach.
David Spero is author of Diabetes: Sugar-coated Crisis, (New Society, 2006) and The Art of Getting Well: Maximizing Health When You Have a Chronic Illness (Hunter House, 2002). He writes for Diabetes Self-Management and Arthritis Self-Management magazines regularly and blogs at www.diabetesselfmanagement.com/blog. See more of David’s work at www.davidsperorn.com.
Type 2 diabetes is by far the most common form (around 90% of all cases) and the one which is increasing the most. It primarily affects overweight people in middle age or later. It’s not uncommon for the affected person to also have a high blood pressure and an abnormal lipid profile. Gestational diabetes is a temporary special case of type 2 diabetes.
^ Jump up to: a b Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ (September 2009). "The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation". Health Technology Assessment. 13 (41): 1–190, 215–357, iii–iv. doi:10.3310/hta13410. PMID 19726018.
Maryland company Orgenesis (ORGS) is developing a proprietary therapeutic platform that transforms adult liver cells into insulin-generating cells to provide patients with independent insulin production. Earlier this year, Orgenesis entered into a partnership with HekaBio K.K. to conduct clinical trials in Japan. The company appears to be moving into licensing the technology to other companies for further development.
Another French company, Valbiotis (FP:ALVAL), has developed the plant-based VALEDIA to reduce the risk of type 2 diabetes by treating patients with pre-diabetic symptoms. The product is based on the active ingredient TOTUM-63, a combination of five plant extracts that work synergistically to address several metabolic factors that play a role in diabetes development.
Transcutaneous electrical nerve stimulation (TENS). Your doctor may prescribe this therapy, which can help prevent pain signals from reaching your brain. TENS delivers tiny electrical impulses to specific nerve pathways through small electrodes placed on your skin. Although safe and painless, TENS doesn't work for everyone or for all types of pain.
Finding relief starts with contacting a Diabetes Relief center and scheduling a consultation. Whether you have Type 1, Type 2, or are pre-diabetic, their medical team can tailor a customized approach for you. Their treatments have helped save patients from uncontrolled blood sugar levels and even future amputations of toes and feet. And because patients report increased energy after treatment, they are more compliant with diet and exercise than they have been in years.
Founded in 2006, Massachusetts-based biotechnology startup Gelesis has raised a total of $118.2 million for developing an oral smart pill. In 2016, the company initially filed an IPO offering of $60 million, but pulled out and instead focused on raising more funding. The technology is based on capsules filled with tiny hydrogel particles that expand between 50 to 100 times their weight in size after absorbing water from the stomach, which results in increased satiety to help obese diabetes patients lose weight and control their sugar metabolism. They are currently undergoing a phase 2 clinical trial on their Gelesis200 product for treating diabetes.
Grains: Grains, especially gluten-containing grains like wheat, contain large amounts of carbohydrates that are broken down into sugar within only a few minutes of consumption. Gluten can cause intestinal inflammation, which affects hormones like cortisol and leptin, and can lead to spikes in blood sugar. I recommend removing all grains from your diet for 90 days as your body adjusts to this healing program. Then you can try bringing sprouted ancient grains back into your diet in small amounts.
Type 1 and type 2 diabetes were identified as separate conditions for the first time by the Indian physicians Sushruta and Charaka in 400–500 CE with type 1 associated with youth and type 2 with being overweight. The term "mellitus" or "from honey" was added by the Briton John Rolle in the late 1700s to separate the condition from diabetes insipidus, which is also associated with frequent urination. Effective treatment was not developed until the early part of the 20th century, when Canadians Frederick Banting and Charles Herbert Best isolated and purified insulin in 1921 and 1922. This was followed by the development of the long-acting insulin NPH in the 1940s.
In type I diabetes, insufficient levels of insulin result from the immune system itself attacking the pancreatic beta cells. On the other hand, while beta cell dysfunction varies widely between type II diabetes patients, insulin resistance is a major part of the disease. Restoring the beta cells of the pancreas to health is the treatment approach these two diseases share to some degree.
This content is provided as a service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. The NIDDK translates and disseminates research findings through its clearinghouses and education programs to increase knowledge and understanding about health and disease among patients, health professionals, and the public. Content produced by the NIDDK is carefully reviewed by NIDDK scientists and other experts.